CORAL GABLES, FL / ACCESSWIRE / August 14, 2017 / Morning markets surged on August 14. News of continued growth in Japan helped boost US markets. In addition to this, President Donald Trump is expected to sign another executive order. This will be to request a trade investigation of China. It would appear that fears of the U.S.-North Korea standoff have subsided and with it has come a bullish move in the market. Joey New York (JOEY), Amarin Corp. Plc. (AMRN), and BTCS Inc. (BTCS) are 3 stocks to watch during this latest market rally.
Joey New York, Inc. (JOEY) announced the expansion of its team on August 8. "We want to set the bar high. It's important to ensure safety at all times and be compliant at every LABB Suite," says Joey Chancis, CEO. "We are revenue driven and utilize our low overhead, high margin business model to drive same store sales growth. To maximize growth while ensuring safety and compliance, we have brought on some very talented individuals on both the business side and the medical side."
With additional locations are being secured in South Florida and California, JOEY New York has seen attention build over the last two weeks. Share price has seen a range of $0.31 to highs of $0.87. Click here for the Full Report on JOEY.
BTCS Inc. (BTCS) is a blockchain technology focused company. With bitcoin prices reaching record highs, the crypto currency and related companies have gained much more attention during recent weeks. On July 19, the company announced the appointment of Jonathon R. Read to the Company's Board of Directors. "Jonathon brings a wealth of public company expertise to our board," commented Charles Allen, CEO of BTCS. "As we move forward on our plans to build a vertically-integrated operation in the burgeoning blockchain space, Jonathon's experience should add tremendous value."
Amarin Corp. Plc (AMRN) shares are up again on Monday. The company announced today that the independent data monitoring committee (DMC) has completed its review of the scheduled pre-specified interim efficacy and safety analysis for the REDUCE-IT cardiovascular outcomes study. In addition to this, there has been a recommendation that the trial continue as planned without modification. "We are pleased that we are nearing completion of the REDUCE-IT study and thank the independent DMC members for their diligence in overseeing this important study," said Steven Ketchum, Ph.D., president of R&D and chief scientific officer of Amarin.
Since hitting lows of $3.04 on August 11, the company's share price has seen a rebound of as much as 14.8% after hitting early morning highs of $3.49.
HeraldFinance.com ("HF") is owned by MAD Media Publishing LLC, a Nevada corporation. HF produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. HF has not been compensated: an affiliate company of HR, MIDAM VENTURES LLC, has been compensated $65,000 by JOEY New York (JOEY) for a period beginning July 31, 2017 and ending August 31, 2017 to publicly disseminate information about JOEY New York (JOEY). We own zero shares.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither HF nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.HeraldFinance.com/.
HF, the Author, and the Reviewer (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect, or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise, arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness, or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.